Hansa Medical Interim Report January–March 2018
IdeS (INN: imlifidase) continues to demonstrate its unprecedented ability to enable transplantation for highly sensitized patientsJanuary-March 2018 in brief · Søren Tulstrup appointed new President and CEO of Hansa Medical, effective March 20, 2018. He has broad and extensive experience as senior executive in the global biopharma industry. Hansa Medical’s acting CEO Ulf Wiinberg reverts to his former role as Chairman of Hansa Medical and Birgit Stattin Norinder reverts to her former role as board member. · Completed enrollment in Hansa Medical’s international multicenter Phase II